Infectious Disease Approved Deal Benchmarks — Europe (2026)

Understanding Infectious Disease Deal Benchmarks at Approved

Approved Infectious Disease licensing deals in Europe territory command a median upfront payment of $906M, with values ranging from $697M at the low end to $1.0B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.6B to $2.0B, with a median of $1.8B. Royalty rates for infectious disease assets at this stage typically fall between 10.3% and 18.4% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.